← 홈

Catalyst · Landscape

향후 6개월 내 primary completion 예정인 활성 임상과 큐레이션·승인 프로그램의 phase 분포입니다. CT.gov completion date 기반 추정이며 공식 readout 일정과 다를 수 있습니다. RSS

파이프라인 Phase 분포

큐레이션·FDA·임상 3건 이상 프로그램 2029개 — catalyst 일정과 별도의 전체 파이프라인 스냅샷입니다.

Preclinical
132
Phase 1
491
Phase 2
979
Phase 3
293
Approved
134

Catalyst target · modality

향후 6개월 catalyst 5건 · 타깃·모달리티 분포

Antibody 5
PD-1
5

향후 6개월 Catalyst(5 / 80)

활성 recruiting/enrolling 임상 · CT.gov completion 기준 · 상위 80건 표시

완료 예정프로그램PhaseStatusEndpoint신뢰도NCT
2026년 9월Opdivo (nivolumab)Antibody · PD-1Phase 1Active, not recruitingNumber (and Percentage) of Outcome Responses After Receiving Nivolumab, Tacrolimus, and Prednisone보통NCT03816332
2026년 9월Opdivo (nivolumab)Antibody · PD-1N/AActive, not recruitingExplore the biomarkers to predict objective response (OR); Explore the biomarkers to predict objective response (OR); Explore the biomarkers to predict objective response (OR); Explore the biomarkers to predict progression-free survival (PFS); Explore the biomarkers to predict progression-free survival (PFS); Explore the biomarkers to predict progression-free survival (PFS); Explore the biomarkers to predict overall survival (OS); Explore the biomarkers to predict overall survival (OS); Explore the biomarkers to predict overall survival (OS)신뢰 높음NCT04603248
2026년 9월Opdivo (nivolumab)Antibody · PD-1Phase 2Active, not recruitingnumber of patients with a response신뢰 높음NCT03282344
2026년 9월Opdivo (nivolumab)Antibody · PD-1Phase 2RecruitingNumber of Patients with a Pathologic Response보통NCT04933903
2026년 9월Opdivo (nivolumab)Antibody · PD-1Phase 1Active, not recruitingIncidence of Treatment-Emergent Adverse Events [Safety and tolerability] of 131-I-MIBG, ch14.18/CHO and Nivolumab in paediatric patients보통NCT02914405
  • 2026년 9월보통
    Opdivo (nivolumab)

    Antibody · PD-1 · Phase 1

    Number (and Percentage) of Outcome Responses After Receiving Nivolumab, Tacrolimus, and Prednisone

    NCT03816332
  • 2026년 9월신뢰 높음
    Opdivo (nivolumab)

    Antibody · PD-1 · N/A

    Explore the biomarkers to predict objective response (OR); Explore the biomarkers to predict objective response (OR); Explore the biomarkers to predict objective response (OR); Explore the biomarkers to predict progression-free survival (PFS); Explore the biomarkers to predict progression-free survival (PFS); Explore the biomarkers to predict progression-free survival (PFS); Explore the biomarkers to predict overall survival (OS); Explore the biomarkers to predict overall survival (OS); Explore the biomarkers to predict overall survival (OS)

    NCT04603248
  • 2026년 9월신뢰 높음
    Opdivo (nivolumab)

    Antibody · PD-1 · Phase 2

    number of patients with a response

    NCT03282344
  • 2026년 9월보통
    Opdivo (nivolumab)

    Antibody · PD-1 · Phase 2

    Number of Patients with a Pathologic Response

    NCT04933903
  • 2026년 9월보통
    Opdivo (nivolumab)

    Antibody · PD-1 · Phase 1

    Incidence of Treatment-Emergent Adverse Events [Safety and tolerability] of 131-I-MIBG, ch14.18/CHO and Nivolumab in paediatric patients

    NCT02914405